{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T10:24:22Z","timestamp":1793874262206,"version":"4.6.1"},"reference-count":53,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,10,4]],"date-time":"2023-10-04T00:00:00Z","timestamp":1696377600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>Genomic profiling to identify myeloid-malignancy-related gene mutations is routinely performed for patients with suspected or definite myeloid malignancies. The most common specimen types in our experience are peripheral blood and bone marrow aspirates. Although primarily intended to identify somatic mutations, not infrequently, potentially clinically significant germline variants are also identified. Confirmation of the germline status of these variants is typically performed by hair follicle or skin fibroblast testing. If the germline variant is classified as a pathogenic or likely pathogenic variant and occurs in a gene known to be associated with a disease relevant to the patient\u2019s phenotype (for example, the identification of a <jats:italic>DDX41<\/jats:italic> pathogenic variant in an individual with acute myeloid leukemia), the management algorithm is typically quite straightforward. Challenging situations may occur such as when the germline variant is classified as a pathogenic or likely pathogenic variant and occurs in a gene not known to be associated with the patient\u2019s phenotype\/presenting complaint. We have encountered several such challenging cases in which potentially clinically significant germline variants were identified on the initial genomic profiling of peripheral blood or bone marrow aspirate. In this article, we present these cases and discuss the genetic counseling and management approaches.<\/jats:p>","DOI":"10.3389\/fonc.2023.1182639","type":"journal-article","created":{"date-parts":[[2023,10,4]],"date-time":"2023-10-04T09:56:16Z","timestamp":1696413376000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":6,"title":["Challenges associated with the identification of germline variants on myeloid malignancy genomic profiling\u2014a Singaporean experience"],"prefix":"10.3389","volume":"13","author":[{"given":"Hui-Lin","family":"Chin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joyce Ching Mei","family":"Lam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dheepa","family":"Christopher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Poon Limei","family":"Michelle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benedict Yan","family":"Junrong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,10,4]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-022-01613-1","article-title":"The 5th edition of the world health organization classification of haematolymphoid tumours: myeloid and histiocytic\/dendritic neoplasms","volume":"36","author":"Khoury","year":"2022","journal-title":"Leukemia"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-08-733196","article-title":"Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel","volume":"129","author":"D\u00f6hner","year":"2017","journal-title":"Blood"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-03-643544","article-title":"The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia","volume":"127","author":"Arber","year":"2016","journal-title":"Blood"},{"key":"B4","doi-asserted-by":"publisher","first-page":"0","DOI":"10.20892\/j.issn.2095-3941.2020.0734","article-title":"Molecular testing for acute myeloid leukemia","volume":"18","author":"Qin","year":"2021","journal-title":"Cancer Biol Med"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2021011354","article-title":"Identification and prioritization of myeloid Malignancy germline variants in a large cohort of adult patients with AML","volume":"139","author":"Yang","year":"2022","journal-title":"Blood"},{"key":"B6","doi-asserted-by":"publisher","first-page":"10086","DOI":"10.1038\/ncomms10086","article-title":"Patterns and functional implications of rare germline variants across 12 cancer types","volume":"6","author":"Lu","year":"2015","journal-title":"Nat Commun"},{"key":"B7","doi-asserted-by":"publisher","first-page":"317","DOI":"10.3892\/ol.2021.12578","article-title":"New progress in the study of germline susceptibility genes of myeloid neoplasms (Review)","volume":"21","author":"Bi","year":"2021","journal-title":"Oncol Lett"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-10-687830","article-title":"Role of RUNX1 in hematological Malignancies","volume":"129","author":"Sood","year":"2017","journal-title":"Blood"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2021015135","article-title":"The genetic landscape of germline DDX41 variants predisposing to myeloid neoplasms","volume":"140","author":"Li","year":"2022","journal-title":"Blood"},{"key":"B10","doi-asserted-by":"publisher","first-page":"9114","DOI":"10.4081\/hr.2021.9114","article-title":"Germline CEBPA mutation in familial acute myeloid leukemia","volume":"13","author":"Boada","year":"2021","journal-title":"Hematol Rep"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-020-0837-6","article-title":"Activating somatic and germline TERT promoter variants in myeloid Malignancies","volume":"35","author":"Nofrini","year":"2021","journal-title":"Leukemia"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2020002953","article-title":"Human GATA2 mutations and hematologic disease: how many paths to pathogenesis","volume":"4","author":"Bresnick","year":"2020","journal-title":"Blood Adv"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020006164","article-title":"Molecular basis of ETV6 -mediated predisposition to childhood acute lymphoblastic leukemia","volume":"137","author":"Nishii","year":"2021","journal-title":"Blood"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1080\/15592294.2020.1809871","article-title":"Germline DNMT3A mutation in familial acute myeloid leukaemia","volume":"16","author":"DiNardo","year":"2021","journal-title":"Epigenetics"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2022007211","article-title":"Clonal hematopoiesis in patients with ANKRD26 or ETV6 germline mutations","volume":"6","author":"Drazer","year":"2022","journal-title":"Blood Advances."},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1136\/jmedgenet-2014-102611","article-title":"Juvenile myelomonocytic leukaemia and Noonan syndrome","volume":"51","author":"Strullu","year":"2014","journal-title":"J Med Genet"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/j.mayocp.2019.12.013","article-title":"Hereditary predisposition to hematopoietic neoplasms","volume":"95","author":"Mangaonkar","year":"2020","journal-title":"Mayo Clinic Proc"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1007\/s11899-022-00681-5","article-title":"Pediatric germline predisposition to myeloid neoplasms","volume":"17","author":"Thompson","year":"2022","journal-title":"Curr Hematol Malig Rep"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2003.03.189","article-title":"American society of clinical oncology policy statement update: genetic testing for cancer susceptibility","volume":"21","year":"2003","journal-title":"JCO"},{"key":"B20","doi-asserted-by":"publisher","first-page":"1044","DOI":"10.1038\/s41467-020-14829-5","article-title":"The complex genetic landscape of familial MDS and AML reveals pathogenic germline variants","volume":"11","author":"Rio-Machin","year":"2020","journal-title":"Nat Commun"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1182\/hematology.2020006910","article-title":"Identifying potential germline variants from sequencing hematopoietic Malignancies","volume":"2020","author":"Kraft","year":"2020","journal-title":"Hematology"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2017013037","article-title":"Prognostic tumor sequencing panels frequently identify germ line variants associated with hereditary hematopoietic Malignancies","volume":"2","author":"Drazer","year":"2018","journal-title":"Blood Advances."},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/j.trecan.2019.11.006","article-title":"Evolving significance of tumor-normal sequencing in cancer care","volume":"6","author":"Mandelker","year":"2020","journal-title":"Trends Cancer."},{"key":"B24","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/j.jmoldx.2016.10.002","article-title":"Standards and guidelines for the interpretation and reporting of sequence variants in cancer","volume":"19","author":"Li","year":"2017","journal-title":"J Mol Diagnostics."},{"key":"B25","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1016\/j.cancergen.2017.01.002","article-title":"Detection of somatic variants in peripheral blood lymphocytes using a next generation sequencing multigene pan cancer panel","volume":"211","author":"Coffee","year":"2017","journal-title":"Cancer Genet"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.582213","article-title":"Next-generation sequencing of DDX41 in myeloid neoplasms leads to increased detection of germline alterations","volume":"10","author":"Bannon","year":"2020","journal-title":"Front Oncol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.3389\/fped.2017.00252","article-title":"Clinical assessment and diagnosis of germline predisposition to hematopoietic Malignancies: the university of chicago experience","volume":"5","author":"Desai","year":"2017","journal-title":"Front Pediatr"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2019-131925","article-title":"Prevalence of inherited cancer predisposition mutations in a cohort of older AML patients enrolled on the beat AML master trial","volume":"134","author":"Borate","year":"2019","journal-title":"Blood"},{"key":"B29","doi-asserted-by":"publisher","first-page":"6944","DOI":"10.1038\/s41598-018-25311-0","article-title":"Quantitation of the cellular content of saliva and buccal swab samples","volume":"8","author":"Theda","year":"2018","journal-title":"Sci Rep"},{"key":"B30","doi-asserted-by":"publisher","first-page":"101191","DOI":"10.1016\/j.beha.2020.101191","article-title":"Myeloid neoplasms with germline predisposition: Practical considerations and complications in the search for new susceptibility loci","volume":"33","author":"Carraway","year":"2020","journal-title":"Best Pract Res Clin Haematol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pcbi.1005965","article-title":"A computational approach to distinguish somatic vs. germline origin of genomic alterations from deep sequencing of cancer specimens without a matched normal","volume":"14","author":"Sun","year":"2018","journal-title":"PloS Comput Biol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1016\/j.gim.2022.04.006","article-title":"ACMG SF v3.1 list for reporting of secondary findings in clinical exome and genome sequencing: A policy statement of the American College of Medical Genetics and Genomics (ACMG)","volume":"24","author":"Miller","year":"2022","journal-title":"Genet Med"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.30248","article-title":"Risks of first and subsequent cancers among TP53 mutation carriers in the National Cancer Institute Li-Fraumeni syndrome cohort: Cancer Risk in TP53 Mutation Carriers","volume":"122","author":"Mai","year":"2016","journal-title":"Cancer"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(21)00425-3","article-title":"Avoidance or adaptation of radiotherapy in patients with cancer with Li-Fraumeni and heritable TP53-related cancer syndromes","volume":"22","author":"Thariat","year":"2021","journal-title":"Lancet Oncol"},{"key":"B35","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1097\/MOH.0000000000000633","article-title":"Germline mutations in MDS\/AML predisposition disorders","volume":"28","author":"Godley","year":"2021","journal-title":"Curr Opin Hematol"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1038\/gim.2015.30","article-title":"Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology","volume":"17","author":"Richards","year":"2015","journal-title":"Genet Med"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1409405","article-title":"Clonal hematopoiesis and blood-cancer risk inferred from blood DNA sequence","volume":"371","author":"Genovese","year":"2014","journal-title":"N Engl J Med"},{"key":"B38","doi-asserted-by":"publisher","first-page":"53","DOI":"10.4103\/singaporemedj.SMJ-2021-329","article-title":"Pitfalls in clinical genetics","volume":"64","author":"Chin","year":"2023","journal-title":"Singapore Med J"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2022008017","article-title":"Revision of RUNX1 variant curation rules","volume":"6","author":"Feurstein","year":"2022","journal-title":"Blood Advances."},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.5858\/arpa.2020-0025-CP","article-title":"Laboratory and clinical implications of incidental and secondary germline findings during tumor testing","volume":"146","author":"Cushman-Vokoun","year":"2022","journal-title":"Arch Pathol Lab Med"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-08-550483","article-title":"How I treat juvenile myelomonocytic leukemia","volume":"125","author":"Locatelli","year":"2015","journal-title":"Blood"},{"key":"B42","unstructured":""},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1182\/asheducation-2018.1.307","article-title":"JMML genomics and decisions","volume":"2018","author":"Niemeyer","year":"2018","journal-title":"Hematology"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.275.1.414","article-title":"The RING finger domain of Cbl is essential for negative regulation of the Syk tyrosine kinase","volume":"275","author":"Ota","year":"2000","journal-title":"J Biol Chem"},{"key":"B45","unstructured":""},{"key":"B46","doi-asserted-by":"publisher","first-page":"839","DOI":"10.3390\/cancers14030839","article-title":"Role of CBL mutations in cancer and non-malignant phenotype","volume":"14","author":"Leardini","year":"2022","journal-title":"Cancers"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1038\/modpathol.2016.75","article-title":"Targeted next-generation sequencing identifies a subset of idiopathic hypereosinophilic syndrome with features similar to chronic eosinophilic leukemia, not otherwise specified","volume":"29","author":"Wang","year":"2016","journal-title":"Mod Pathol"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1002\/ajmg.1320210313","article-title":"Noonan syndrome: The changing phenotype","volume":"21","author":"Allanson","year":"1985","journal-title":"Am J Med Genet"},{"key":"B49","first-page":"1993","article-title":"DDX41-associated familial myelodysplastic syndrome and acute myeloid leukemia [Internet]","volume-title":"GeneReviews\u00ae","author":"Churpek","year":"2021"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2016.310","article-title":"Re-emergence of acute myeloid leukemia in donor cells following allogeneic transplantation in a family with a germline DDX41 mutation","volume":"31","author":"Berger","year":"2017","journal-title":"Leukemia"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-018-0051-y","article-title":"Universal genetic testing for inherited susceptibility in children and adults with myelodysplastic syndrome and acute myeloid leukemia: are we there yet","volume":"32","author":"Tawana","year":"2018","journal-title":"Leukemia"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1097\/HS9.0000000000000321","article-title":"Nordic guidelines for germline predisposition to myeloid neoplasms in adults: recommendations for genetic diagnosis, clinical management and follow-up","volume":"3","author":"Baliakas","year":"2019","journal-title":"HemaSphere"},{"key":"B53","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1001\/jamaoncol.2020.0016","article-title":"The ethics of delivering precision medicine\u2014Pretest counseling and somatic genomic testing","volume":"6","author":"Borno","year":"2020","journal-title":"JAMA Oncol"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2023.1182639\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,4]],"date-time":"2023-10-04T09:56:19Z","timestamp":1696413379000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2023.1182639\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,4]]},"references-count":53,"alternative-id":["10.3389\/fonc.2023.1182639"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2023.1182639","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,10,4]]},"article-number":"1182639"}}